Ping An of China CSI HK Dividend ETF(03070.HK) fell 1.28% to HKD 43.240
Newtimespace News, as of 15:40 on April 30, Ping An of China CSI HK Dividend ETF(03070.HK) was quoted at HKD 43.240, down 1.28%. The ETF opened at HKD 44.000, with a high of HKD 44.000 and a low of HKD 43.220. The latest trading volume was 172,700 units, with a turnover of HKD 7.4948 million, and a turnover rate of 0.67%. The latest NAV per unit is HKD 43.745, with a premium rate of 0.13%. The asset size is approximately HKD 1.126 billion, and the total issuance is 25.75 million units.
Ping An of China CSI HK Dividend ETF(03070.HK) tracks the CSI Hong Kong Dividend Index, which is compiled and published by China Securities Index Co., Ltd. The index aims to reflect the overall performance of high dividend-yield stocks in the Hong Kong market. Its selection universe covers companies listed in Hong Kong with a stable dividend distribution record. The index constituents include high dividend-yield sectors such as finance, property, and utilities, making it an important benchmark for gauging the performance of Hong Kong's high dividend-yield stocks.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- TRULY INT'L (00732.HK): Unaudited July Turnover Approximately HK$1.259 Billion, Down 14.2% YoY
- SKYWORTH GROUP (00751.HK): Expected Unaudited Profit After Tax for First Half to Rise by No Less Than 170% Year-on-Year
- BAIYUNSHAN PH(00874.HK): Subsidiary Zhongyi Pharmaceutical Obtains Revised Drug Production Licence with Removal of Production Site and Change of Production Person‑in‑Charge
- SBP GROUP(01177.HK): NDA for BCL‑2 Inhibitor TQB3909 Accepted, for Treatment of CLL/SLL
- Autonomous Driving Concept Stocks Watch | XPENG-W (09868.HK) Trades Lower in Afternoon; Cumulative Global New Vehicle Deliveries Surpass 1.2 Million Units as of July